MENU
At SEEDSUPPLY, we are redefining what’s possible in drug discovery. Founded in 2017 as a spin-off from Takeda, we specialize in identifying hit compounds and drug targets that pave the way for first-in-class therapeutics. Leveraging deep scientific expertise and proprietary technologies, we accelerate innovation in pharmaceutical research worldwide.
Our core strength is our Improved Affinity Selection Mass Spectrometry (ASMS) platform—a next-generation technology that enables direct binding assays on membrane proteins such as SLC transporters, GPCRs, and ion channels, without the need for solubilization. By preserving the native structure of these complex targets, we provide more physiologically relevant screening, overcoming a long-standing bottleneck in small-molecule discovery.
Beyond membrane proteins, SEEDSUPPLY offers comprehensive target identification services, performing binding assays against a 17,000-protein library to uncover novel targets and elucidate mechanisms of action. This allows us to accelerate target discovery even for compounds with unknown modes of action.
Combined with our proprietary 400,000-compound screening library, our integrated platform enables:
From binder selection to target discovery, SEEDSUPPLY provides end-to-end solutions that empower researchers to unlock new therapeutic possibilities.
SEEDSUPPLY – Advancing Drug Discovery Beyond Boundaries.
Dr. Tarui has been involved in drug discovery research especially hit finding for 20 years at Takeda Pharmaceutical Company. A typical hit compound is the seed compound of vonoprazan (the world’s first potassium competitive acid blocker).
Dr. Tarui has established SEEDSUPPLY as spin-out from Takeda in 2017 to improve the early drug discovery process for small molecule drugs by using binder selection technology.
Dr. Tarui has advocated a groundbreaking drug discovery that leverages the binder collection.
Since joining Takeda Pharmaceutical Company in 1989, Nakayama has been engaged in the screening and optimization of novel compounds for both pharmaceuticals and agrochemicals within the research division. He has been with SEEDSUPPLY INC. since its founding in 2017, when the company spun out from Takeda. Over the course of his career, Nakayama has worked on a wide variety of screening targets, including GPCRs, transporters, ion channels, and diverse enzyme classes.
SEEDSUPPLY is a supplier of drug seeds located in Shonan Research Park in Fujisawa, Japan.
26-1, Muraoka-Higashi 2-Chome
Fujisawa, Kanagawa
251-0012, Japan
Phone: +81-466-54-5007
Fax: +81-466-54-5008
Email: info.ss@seedsupply.co.jp
